Hepatitis C Virus Vaccine: Challenges and Prospects
Open Access
- 17 February 2020
- Vol. 8 (1), 90
- https://doi.org/10.3390/vaccines8010090
Abstract
The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.Funding Information
- Medical Research Council (MR/R010307/1)
This publication has 193 references indexed in Scilit:
- Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccineThe Lancet Infectious Diseases, 2012
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsVaccine, 2010
- Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent ReinfectionGastroenterology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C VirusGastroenterology, 2009
- Human occludin is a hepatitis C virus entry factor required for infection of mouse cellsNature, 2009
- Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis CProceedings of the National Academy of Sciences of the United States of America, 2007
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature, 2007
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimerasProceedings of the National Academy of Sciences of the United States of America, 2006